These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Chakrabarti R; Vikramadithyan RK; Misra P; Hiriyan J; Raichur S; Damarla RK; Gershome C; Suresh J; Rajagopalan R Br J Pharmacol; 2003 Oct; 140(3):527-37. PubMed ID: 12970088 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. Ebdrup S; Pettersson I; Rasmussen HB; Deussen HJ; Frost Jensen A; Mortensen SB; Fleckner J; Pridal L; Nygaard L; Sauerberg P J Med Chem; 2003 Apr; 46(8):1306-17. PubMed ID: 12672231 [TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists. Oon Han H; Kim SH; Kim KH; Hur GC; Joo Yim H; Chung HK; Ho Woo S; Dong Koo K; Lee CS; Sung Koh J; Kim GT Bioorg Med Chem Lett; 2007 Feb; 17(4):937-41. PubMed ID: 17157019 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents. Neogi P; Lakner FJ; Medicherla S; Cheng J; Dey D; Gowri M; Nag B; Sharma SD; Pickford LB; Gross C Bioorg Med Chem; 2003 Sep; 11(18):4059-67. PubMed ID: 12927868 [TBL] [Abstract][Full Text] [Related]
8. Novel thieno oxazine analogues as antihyperglycemic and lipid modulating agents. Das SK; Reddy KA; Abbineni C; Iqbal J; Suresh J; Premkumar M; Chakrabarti R Bioorg Med Chem Lett; 2003 Feb; 13(3):399-403. PubMed ID: 12565938 [TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. Brooks DA; Etgen GJ; Rito CJ; Shuker AJ; Dominianni SJ; Warshawsky AM; Ardecky R; Paterniti JR; Tyhonas J; Karanewsky DS; Kauffman RF; Broderick CL; Oldham BA; Montrose-Rafizadeh C; Winneroski LL; Faul MM; McCarthy JR J Med Chem; 2001 Jun; 44(13):2061-4. PubMed ID: 11405642 [TBL] [Abstract][Full Text] [Related]
10. DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities. Vikramadithyan RK; Hiriyan J; Suresh J; Gershome C; Babu RK; Misra P; Rajagopalan R; Chakrabarti R Obes Res; 2003 Feb; 11(2):292-303. PubMed ID: 12582227 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid. Cai ZF; Liu Q; Li PP; Guo ZR; Shen ZF Acta Pharmacol Sin; 2006 May; 27(5):597-602. PubMed ID: 16626515 [TBL] [Abstract][Full Text] [Related]
14. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Chakrabarti R; Misra P; Vikramadithyan RK; Premkumar M; Hiriyan J; Datla SR; Damarla RK; Suresh J; Rajagopalan R Eur J Pharmacol; 2004 May; 491(2-3):195-206. PubMed ID: 15140637 [TBL] [Abstract][Full Text] [Related]
15. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. Skrumsager BK; Nielsen KK; Müller M; Pabst G; Drake PG; Edsberg B J Clin Pharmacol; 2003 Nov; 43(11):1244-56. PubMed ID: 14551179 [TBL] [Abstract][Full Text] [Related]